* Tandem Diabetes Care Inc TNDM.OQ reported a quarterly
adjusted
loss of 1 cent per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-1.92. The mean expectation of
sixteen analysts for the quarter was for a loss of 76 cents per
share. Wall Street expected results to range from -85 cents
to -58 cents per share.
* Revenue rose 13.2% to $191.67 million from a year ago;
analysts
expected $173.64 million.
* Tandem Diabetes Care Inc's reported EPS for the quarter
was a
loss of 65 cents.
* The company reported a quarterly loss of $42.72 million.
* Tandem Diabetes Care Inc shares had risen by 2.2% this
quarter and gained 22.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 62.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 6
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Tandem Diabetes
Care Inc is $39.50
This summary was machine generated from LSEG data May 2 at 10:38
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.76 -0.01 Beat
Dec. 31 2023 -0.34 -0.27 Beat
Sep. 30 2023 -0.34 -0.38 Missed
Jun. 30 2023 -0.53 -0.55 Missed